CY1107679T1 - Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar - Google Patents

Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar

Info

Publication number
CY1107679T1
CY1107679T1 CY20071100810T CY071100810T CY1107679T1 CY 1107679 T1 CY1107679 T1 CY 1107679T1 CY 20071100810 T CY20071100810 T CY 20071100810T CY 071100810 T CY071100810 T CY 071100810T CY 1107679 T1 CY1107679 T1 CY 1107679T1
Authority
CY
Cyprus
Prior art keywords
alkyl
substituted
agonors
ppar
oxazolyl
Prior art date
Application number
CY20071100810T
Other languages
Greek (el)
English (en)
Inventor
Dawn Alisa Brooks
Alexander Glenn Godfrey
Sarah Beth Jones
James Ray Mccarthy
Christopher John Rito
Leonard Larry Winneroski Jr
Yanping Xu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1107679T1 publication Critical patent/CY1107679T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CY20071100810T 2000-08-23 2007-06-19 Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar CY1107679T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
EP01963733A EP1313716B1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (1)

Publication Number Publication Date
CY1107679T1 true CY1107679T1 (el) 2013-04-18

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100810T CY1107679T1 (el) 2000-08-23 2007-06-19 Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar

Country Status (26)

Country Link
US (2) US6930120B2 (enExample)
EP (1) EP1313716B1 (enExample)
JP (1) JP2004506721A (enExample)
KR (1) KR20030027054A (enExample)
CN (1) CN1471517A (enExample)
AT (1) ATE361283T1 (enExample)
AU (1) AU2001284659A1 (enExample)
BR (1) BR0113409A (enExample)
CA (1) CA2418104A1 (enExample)
CY (1) CY1107679T1 (enExample)
CZ (1) CZ2003482A3 (enExample)
DE (1) DE60128239T2 (enExample)
DK (1) DK1313716T3 (enExample)
EA (1) EA200300286A1 (enExample)
EC (1) ECSP034504A (enExample)
ES (1) ES2286137T3 (enExample)
HU (1) HUP0300857A3 (enExample)
IL (1) IL154110A0 (enExample)
MX (1) MXPA03001558A (enExample)
NO (1) NO20030729L (enExample)
NZ (1) NZ523804A (enExample)
PL (1) PL360744A1 (enExample)
PT (1) PT1313716E (enExample)
SK (1) SK1872003A3 (enExample)
WO (1) WO2002016331A1 (enExample)
ZA (1) ZA200300570B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
CA2418134A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
PL374818A1 (en) 2002-07-03 2005-10-31 F.Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
WO2004024726A1 (en) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CA2503117C (en) 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
CA2418134A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
ECSP034504A (es) 2003-04-25
PL360744A1 (en) 2004-09-20
DE60128239D1 (de) 2007-06-14
ES2286137T3 (es) 2007-12-01
AU2001284659A1 (en) 2002-03-04
NO20030729L (no) 2003-04-02
NZ523804A (en) 2004-09-24
EP1313716A1 (en) 2003-05-28
BR0113409A (pt) 2003-07-01
EP1313716B1 (en) 2007-05-02
US20050245584A1 (en) 2005-11-03
WO2002016331A1 (en) 2002-02-28
JP2004506721A (ja) 2004-03-04
MXPA03001558A (es) 2003-06-06
CN1471517A (zh) 2004-01-28
CZ2003482A3 (cs) 2003-05-14
HUP0300857A2 (hu) 2003-10-28
DK1313716T3 (da) 2007-08-27
NO20030729D0 (no) 2003-02-14
PT1313716E (pt) 2007-07-11
ZA200300570B (en) 2004-04-21
US6930120B2 (en) 2005-08-16
IL154110A0 (en) 2003-07-31
US7345070B2 (en) 2008-03-18
US20040097590A1 (en) 2004-05-20
DE60128239T2 (de) 2008-01-10
HUP0300857A3 (en) 2007-03-28
EA200300286A1 (ru) 2003-08-28
SK1872003A3 (en) 2003-07-01
ATE361283T1 (de) 2007-05-15
CA2418104A1 (en) 2002-02-28
KR20030027054A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
DE60128239D1 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE60129712D1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
RU2006101890A (ru) Производные тиазолилпиперидина в качестве ингибиторов мпб
ATE51223T1 (de) Derivate der 2-azetidinon-1-sulfonsaeure, ihre herstellung und verwendung.
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
ATE239619T1 (de) Aufzeichnungsmaterial sowie bilddruckverfahren das dieses material verwendet
RU98117621A (ru) Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт
ATE295841T1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
DE60020573D1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
EA200101224A1 (ru) Производные пурина, способ их получения и содержащие их фармацевтические композиции
ATE374748T1 (de) Phenylcyclohexylpropanolaminderivate, deren herstellung und therapeutsche anwendung
SE9703379D0 (sv) New compounds
ATE95816T1 (de) 2-((4-piperidinyl)methyl>-1,2,3,4tetrahydroisochinolin-derivate, ihre herstellung und ihre therapeutische verwendung.
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
PT1050531E (pt) Compostos piridinicos ou piperidinicos substituidos para o tratamento de doencas neurodegenerativas
NO20062936L (no) Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav
CY1107794T1 (el) Νeα μeθοδος παρασκευhς παραγωγων εποθιλονης
SE7609459L (sv) Triflourmetylfenoxi-fenylkarbamider till anvendning som herbicider och sett for deras framstellning
SE8405430L (sv) 7-acylindolforeningar, lempade som mellanprodukter vid synteser av 7-acylindolin-2-oner
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
DK272684D0 (da) Tetrahydro-beta-carbolin-derivater og fremgangsmaade til fremstilling deraf
DE60121817D1 (de) Blockade der natriumkanäle durch phenolderivate
CY1107100T1 (el) ΚΙΝΝΑΜΩΜΙΚΑ ΠΑΡΑΓΩΓΑ ΒΕΝΖΟ[b] ΠΥΡΑΝΟ [3,2-h] ΑΚΡΙΔΙΝ-7-OΝΗΣ, ΜEΘΟΔΟΣ ΠΑΡΑΣΚΕΥHΣ ΑΥΤΩΝ ΚΑΙ ΟΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠΕΡΙΕΧΟΥΝ
ES2064692T3 (es) Nuevos derivados de la 2-acetidinona 1,3,4-trisustituidas y su procedimiento de sintesis asimetrica.
DE68905222D1 (de) 7-(1-imidazolyl)-1,4-dihydro-4-oxo-6,8-difluoro-1-cyclopropylchinolincarbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel.